How AI is supercharging drug development

Artificial intelligence is revolutionizing drug development by slashing preclinical costs and timelines by up to 70%, according to a TD Cowen survey of 80 biopharma leaders. This shift is driving demand for advanced software and tools, accelerating the pace of early-stage pharmaceutical research and potentially leading to faster, more efficient drug discovery. The implications are huge, as this AI-driven automation could reshape the entire landscape of pharmaceutical innovation, promising quicker access to life-saving treatments.